Table 1 Clinicopathologic characteristics of analysed patients. Patient characteristics for 7690 prostate cancer patients identified from the PCOR-VIC registry with complete EPIC-26 data between September 2014 and December 2018 inclusive
|  | Complete (n = 7690) N (%) |
|---|---|
Age – median (IQR) | 67 (61–72) |
Gleason Risk Group | |
  ISUP1 | 1964 (25.5) |
  ISUP2 | 2730 (35.5) |
  ISUP3 | 1399 (18.2) |
  ISUP4 | 705 (9.2) |
  ISUP5 | 892 (11.6) |
T stage | |
  T1 | 3299 (42.9) |
  T2 | 1875 (24.4) |
  T3 | 508 (6.6) |
  T4 | 48 (0.6) |
  Not recorded | 1960 (25.5) |
N stage | |
  0 | 7262 (94.4) |
  1 | 312 (4.1) |
  Not recorded | 116 (1.5) |
M stage | |
  0 | 7276 (94.6) |
  1 | 346 (4.5) |
  Not recorded | 68 (0.9) |
  PSA at diagnosis | 6.8 (4.9–10.2) |
NCCN risk group | |
  low | 1639 (21.3) |
  intermediate | 3737 (48.6) |
  high | 1549 (20.1) |
  nodal | 158 (2.1) |
  metastatic | 346 (4.5) |
  Not classifiable | 261 (3.4) |
Treatment modality | |
  Prostatectomy | 3985 (51.8) |
  WWAS | 1831 (23.8) |
  Radiation therapy | 1415 (18.4) |
  ADT | 370 (4.8) |
  Other | 89 (1.2) |
Remoteness | |
  Major Cities | 5461 (71) |
  Inner Regional | 1750 (22.8) |
  Outer Regional | 479 (6.2) |
  IRSAD – median (IQR) | 1038 (974–1096) |